Mesenchymal Stem Cells and C-type Natriuretic Peptide Signaling: A Proposal for a New Treatment Approach for Skeletal Dysplasias

Author(s): Murat Serkant Unal, Ahmet Cevik Tufan

Journal Name: Current Stem Cell Research & Therapy

Volume 11 , Issue 6 , 2016

Become EABM
Become Reviewer
Call for Editor


Endochondral ossification is under the regulation of endocrine, paracrine and otocrine factors including transforming growth factor-β superfamily members, fibroblast growth factors, retinoids, products of hedgehog gene, parathyroid hormone-related peptide, molecules involved in cell adhesion, and extracellular matrix components. Natriuretic peptide receptor-B, and its ligand C-type natriuretic peptide have also been implicated in the regulation of limb bone development. Results of recent studies are promising in terms of systemic elevation of C-type natriuretic peptide level inducing growth. In addition, same strategy also overcomes the dwarf phenotype of achondroplasia, the most frequently seen skeletal dysplasia in human, in a mouse model. Based on this literature and a series of recent experiments discussed here, this perspective underlines the abundant C-type natriuretic peptide expression in trabecular bone derived mesenchymal stem cells of human, chicken, and rat origin, and proposes the potential use of mesenchymal stem cells as a part of growth inducing treatment strategy in osteochondrodisyplasias in the future.

Keywords: Achondroplasia, C-type natriuretic peptide, dwarfism, endochondral ossification, mesenchymal stem cells, natriuretic peptide receptor-B, osteochondrodisyplasia, skeletal dysplasia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 16 June, 2016
Page: [513 - 521]
Pages: 9
DOI: 10.2174/1574888X10666150202145939
Price: $65

Article Metrics

PDF: 39
PRC: 1